Enteral Docosahexaenoic Acid and Retinopathy of Prematurity: A Randomized Clinical Trial

Background Retinopathy of prematurity (ROP) is a disorder of the retina of low‐birth‐weight preterm infants that potentially leads to blindness. Docosahexaenoic acid (DHA), is protective in experimental models, but its administration as part of parenteral nutrition has shown inconsistent results. We...

Full description

Saved in:
Bibliographic Details
Published in:JPEN. Journal of parenteral and enteral nutrition 2019-09, Vol.43 (7), p.874-882
Main Authors: Bernabe‐García, Mariela, Villegas‐Silva, Raúl, Villavicencio‐Torres, Astrid, Calder, Philip C., Rodríguez‐Cruz, Maricela, Maldonado‐Hernández, Jorge, Macías‐Loaiza, Denisse, López‐Alarcón, Mardia, Inda‐Icaza, Patricia, Cruz‐Reynoso, Leonardo
Format: Article
Language:English
Subjects:
DHA
neonate
omega‐3 fatty acids
premature infant
preterm
retinopathy
ROP
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Retinopathy of prematurity (ROP) is a disorder of the retina of low‐birth‐weight preterm infants that potentially leads to blindness. Docosahexaenoic acid (DHA), is protective in experimental models, but its administration as part of parenteral nutrition has shown inconsistent results. We test the effect of enteral DHA to prevent ROP and/or severity and to reduce hospital stay. Methods This was a double‐blind parallel clinical trial. Preterm infants (n = 110; 55 per group) with birth weight
ISSN:0148-6071
1941-2444
DOI:10.1002/jpen.1497